TheraSTrat

TheraStrat is a precision oncology company dedicated to overcoming drug resistance in cancer treatment. Headquartered in Allschwil, Switzerland, the company utilizes a proprietary functional genomics platform to identify novel therapeutic targets that allow tumors to bypass existing therapies. By focusing on these resistance mechanisms, TheraStrat develops first-in-class small molecule drugs designed to restore sensitivity to treatment or provide new options for patients with refractory disease. The company's research is particularly focused on melanoma and other solid tumors where resistance to targeted and immunotherapies is a significant clinical challenge. TheraStrat's approach integrates high-throughput screening with sophisticated bioinformatics to accelerate the transition from target discovery to clinical development.